logo

For the Inventor, By the Inventor

Mountain View, CA, United States of America

Igm Biosciences, Inc.


USPTO Granted Patents = 22

% Expired Patents = 9.1



Trademarks = 3

Forward Citations = 141

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Bruce Alan Keyt (20 out of 43 patents)

silverMedal Ramesh Baliga (16 out of 29 patents)

bronzeMedal Leonard G Presta (10 out of 215 patents)

4.  Fen Zhang (6 out of 10 patents)

5.  Dean Ng (5 out of 5 patents)

6.  Stephen Fitzhugh Carroll (3 out of 30 patents)

7.  Ole Olsen (2 out of 35 patents)

8.  Beatrice Tien-Yi Wang (2 out of 3 patents)

9.  Marcia M Bieber (2 out of 7 patents)

10.  Nelson N H Teng (2 out of 3 patents)

11.  Dan T Stinchcomb (2 out of 57 patents)

12.  Max Allen Schwarzer (2 out of 3 patents)

13.  Neelima M Bhat (2 out of 7 patents)

14.  Omar Duramad (1 out of 7 patents)

15.  Rency Yoshimura (1 out of 1 patent)


22 patents:

1. 12649791 - IGM FC AND J-CHAIN MUTATIONS THAT AFFECT IGM SERUM HALF-LIFE (2026-06-09),
2. 12486336 - BINDING MOLECULES WITH MODIFIED J-CHAIN (2025-12-02),
3. 11639389 - Binding molecules with modified J-chain (2023-05-02),
4. 11578131 - Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules (2023-02-14),
5. 11555075 - Modified J-chain (2023-01-17),
6. 11542342 - Binding molecules with modified J-chain (2023-01-03),
7. 11535664 - Multi-valent hepatitis B virus antigen binding molecules and uses thereof (2022-12-27),
8. 11401337 - Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function (2022-08-02),
9. 11192941 - Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof (2021-12-07),
10. 10975147 - Modified J-chain (2021-04-13),
11. 10954302 - Anti-PD-L1 antibodies (2021-03-23),
12. 10899835 - IgM Fc and J-chain mutations that affect IgM serum half-life (2021-01-26),
13. 10822399 - IgA multi-specific binding molecules (2020-11-03),
14. 10787520 - Multimeric bispecific binding molecules specific for CD20 and CD3 (2020-09-29),
15. 10689449 - Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof (2020-06-23),
Company Overview
Igm Biosciences, Inc. is a biotechnology company based in Mountain View, California, focused on the development of innovative therapies for cancer and autoimmune diseases. The company specializes in the design and manufacturing of engineered antibodies, leveraging its proprietary technology platform to create next-generation immunotherapies. With a commitment to advancing treatment options, Igm Biosciences aims to address unmet medical needs through its research in antibody-based therapeutics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Igm Biosciences, Inc. USPTO Patent Assignee Logo
22 Patents

#142 in Mountain View, CA

#3,582 in California

#15,021 in US

#28,749 in the World

Mountain View, CA (US)
Mountain View, CA, United States of America

Igm Biosciences, Inc.

Forward Citations = 141

17 inventors:

goldMedal Bruce Alan Keyt (20 out of 43 patents)

silverMedal Ramesh Baliga (16 out of 29 patents)

bronzeMedal Leonard G Presta (10 out of 215 patents)

4.  Fen Zhang (6 out of 10 patents)

5.  Dean Ng (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Igm Biosciences, Inc.. Retrieved from https://idiyas.com/company/igm-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…